Evolocumab betters ezetimibe for lowering LDL in statin-intolerant patients

WASHINGTON – Evolocumab, an investigational fully human monoclonal antibody, was associated with markedly greater LDL cholesterol reductions than ezetimibe in a phase III clinical trial of...